SOM Biotech strengthens its management team with the appointment of Catherine Scart as Chief Medical Officer and Kevin McAllister as Chief Scientific Officer.
Therefore, Catherine Scart MD will join SOM Biotech management team as Chief Medical Officer and will assume responsibility for the company´s clinical trials and lead the pipeline development with a special focus on leveraging on SOMs proprietary technology to develop valuable drug candidates. Prior to joining SOM Biotech, Catherine Scart served as Head of Clinical Development at Bioproject, a French R&D company where she led the clinical development plan and ensured the execution of clinical trials, particularly in the areas of neurodegenerative and orphan diseases. Catherine Scart has a strong background working for international biopharmaceutical companies providing key medical and scientific support to launch innovative compounds, managing all processes needed to ensure the effective and successful completion of the companies´ pipeline development strategy.
Kevin McAllister PhD MBA will join SOM Biotech management team as Chief Scientific Officer, contributing with his extensive experience in drug discovery and development to strengthen the nonclinical and clinical scientific and technical expertise. Kevin McAllister joins SOM Biotech from Neurenable GmbH, where he was Managing Director and consulting to biotech in the EU and USA. Prior to this Kevin was Executive Director in the Neuroscience Disease Area at Novartis Institutes for Biomedical Research, and Principal Medical Scientific Expert in the Novartis Neuroscience Clinical Development Franchise.
Raul Insa, CEO of SOM Biotech: “I´m delighted that Catherine and Kevin are joining SOM Biotech. Both bring very valuable and extensive experience to complement the expertise of our existing team. They will play a key role as we continue with the progress of our pipeline and with the implementation of our strategic plan to grow and position SOM Biotech as a leading biopharma worldwide”.